Immune cell labelling and tracking: implications for adoptive cell transfer therapies.
Adoptive cell transfer
Cell labelling
Immunotherapy
Molecular imaging
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
03 Feb 2021
03 Feb 2021
Historique:
received:
23
06
2020
accepted:
04
12
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer, proved to be successful in humans. Indeed, after the approval of anti-CD19 CAR-T cell therapy, researchers are trying to extend this approach to other cancer or cell types. This review focuses on the different approaches to non-invasively monitor the biodistribution, trafficking and fate of immune therapeutic cells, evaluating their efficacy at preclinical and clinical stages. PubMed and Scopus databases were searched for published articles on the imaging of cell tracking in humans and preclinical models. Labelling specific immune cell subtypes with specific radiopharmaceuticals, contrast agents or optical probes can elucidate new biological mechanisms or predict therapeutic outcome of adoptive cell transfer therapies. To date, no technique is considered the gold standard to image immune cells in adoptive cell transfer therapies.
Sections du résumé
BACKGROUND
BACKGROUND
The understanding of the role of different immune cell subsets that infiltrate tumors can help researchers in developing new targeted immunotherapies to reactivate or reprogram them against cancer. In addition to conventional drugs, new cell-based therapies, like adoptive cell transfer, proved to be successful in humans. Indeed, after the approval of anti-CD19 CAR-T cell therapy, researchers are trying to extend this approach to other cancer or cell types.
MAIN BODY
METHODS
This review focuses on the different approaches to non-invasively monitor the biodistribution, trafficking and fate of immune therapeutic cells, evaluating their efficacy at preclinical and clinical stages. PubMed and Scopus databases were searched for published articles on the imaging of cell tracking in humans and preclinical models.
CONCLUSION
CONCLUSIONS
Labelling specific immune cell subtypes with specific radiopharmaceuticals, contrast agents or optical probes can elucidate new biological mechanisms or predict therapeutic outcome of adoptive cell transfer therapies. To date, no technique is considered the gold standard to image immune cells in adoptive cell transfer therapies.
Identifiants
pubmed: 33537909
doi: 10.1186/s41181-020-00116-7
pii: 10.1186/s41181-020-00116-7
pmc: PMC7859135
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
7Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 20411
Références
Nanomedicine (Lond). 2015;10(11):1761-74
pubmed: 26080698
J Am Chem Soc. 2011 Mar 9;133(9):2955-61
pubmed: 21314118
J Occup Environ Med. 2016 Dec;58(12):1159-1166
pubmed: 27930472
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):842-8
pubmed: 20198473
Immunol Lett. 2019 Jul;211:13-22
pubmed: 31091431
Angew Chem Int Ed Engl. 2005 Mar 11;44(12):1813-5
pubmed: 15723362
Q J Nucl Med Mol Imaging. 2018 Mar;62(1):56-77
pubmed: 29191000
Eur J Nucl Med Mol Imaging. 2003 Jul;30(7):1038-44
pubmed: 12567250
Oncotarget. 2015 Sep 15;6(27):23735-47
pubmed: 26124178
Science. 2005 Jan 28;307(5709):538-44
pubmed: 15681376
Nat Rev Cancer. 2003 Jan;3(1):35-45
pubmed: 12509765
Immune Netw. 2020 Mar 09;20(2):e14
pubmed: 32395366
Int J Nanomedicine. 2013;8:555-68
pubmed: 23429995
Front Immunol. 2018 Feb 15;9:283
pubmed: 29497427
Blood. 2003 Jan 15;101(2):640-8
pubmed: 12393519
J Nucl Med. 2015 Oct;56(10):1575-80
pubmed: 26272812
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1816-1831
pubmed: 29850929
Blood. 2014 Aug 14;124(7):1081-8
pubmed: 25006133
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3030-5
pubmed: 11867752
Oncotarget. 2018 Jul 13;9(54):30268-30278
pubmed: 30100988
J Neurosci Res. 2003 Aug 1;73(3):284-95
pubmed: 12868062
Nucl Med Mol Imaging. 2015 Mar;49(1):3-10
pubmed: 25774232
Transl Res. 2017 Sep;187:11-21
pubmed: 28641074
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Cancer Res. 2010 Aug 1;70(15):6109-13
pubmed: 20631071
Anal Chem. 2014 Nov 18;86(22):11403-9
pubmed: 25341054
Blood. 2007 Mar 15;109(6):2649-56
pubmed: 17095616
Mol Imaging. 2014;13:
pubmed: 25248941
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
J Magn Reson Imaging. 1997 Nov-Dec;7(6):1140-5
pubmed: 9400860
Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):835-41
pubmed: 20198474
Cancer Biother Radiopharm. 2012 Dec;27(10):719-28
pubmed: 23009582
Cancer Immunol Immunother. 2001 Nov;50(9):477-82
pubmed: 11761442
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5
pubmed: 19211796
J Clin Med. 2019 Oct 12;8(10):
pubmed: 31614774
Trends Biotechnol. 2010 Jul;28(7):363-70
pubmed: 20427096
Molecules. 2017 May 26;22(6):
pubmed: 28587110
Bioessays. 2010 Sep;32(9):756-67
pubmed: 20652893
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
Stem Cells. 2002;20(6):501-13
pubmed: 12456958
Cancer Res. 1993 Dec 15;53(24):5867-71
pubmed: 8261395
Am Soc Clin Oncol Educ Book. 2018 May 23;38:169-178
pubmed: 30231380
Eur Radiol. 2008 Oct;18(10):2021-32
pubmed: 18506449
Front Pharmacol. 2015 Feb 12;6:21
pubmed: 25729364
J Clin Med. 2019 May 14;8(5):
pubmed: 31091813
Mol Ther Oncolytics. 2016 Jun 15;3:16015
pubmed: 27347557
Cytotherapy. 2012 Aug;14(7):830-40
pubmed: 22458956
Eur Radiol. 2005 Jan;15(1):4-13
pubmed: 15616814
Biores Open Access. 2019 Mar 29;8(1):32-44
pubmed: 30944770
Contrast Media Mol Imaging. 2019 Mar 25;2019:4368342
pubmed: 31019414
Leukemia. 2018 Feb;32(2):520-531
pubmed: 28725044
Semin Nucl Med. 2017 May;47(3):286-303
pubmed: 28417857
Methods Mol Biol. 2015;1239:231-40
pubmed: 25408409
Eur J Nucl Med Mol Imaging. 2012 May;39(5):745-9
pubmed: 22297458
Oncoimmunology. 2017 Feb 6;6(4):e1287246
pubmed: 28507794
Q J Nucl Med Mol Imaging. 2020 Mar;64(1):85-95
pubmed: 31140233
Dalton Trans. 2018 Jul 17;47(28):9283-9293
pubmed: 29796500
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Biol Reprod. 2013 Mar 14;88(3):61
pubmed: 23390162
Eur J Nucl Med Mol Imaging. 2004 Mar;31(3):403-7
pubmed: 14685783
Histochem Cell Biol. 2010 May;133(5):481-91
pubmed: 20372919
Mol Imaging. 2009 Jan-Feb;8(1):15-26
pubmed: 19344572
Radiol Med. 2014 Apr;119(4):269-76
pubmed: 24311191
Magn Reson Med. 2008 Dec;60(6):1292-7
pubmed: 19030162
J Nucl Med. 1998 Nov;39(11):2003-11
pubmed: 9829598
J Nucl Med. 2018 Oct;59(10):1531-1537
pubmed: 29728514
Mol Ther. 2017 Aug 2;25(8):1769-1781
pubmed: 28668320
J Am Chem Soc. 2008 Mar 5;130(9):2832-41
pubmed: 18266363
Oncoimmunology. 2016 Nov 22;5(12):e1250051
pubmed: 28123890
Circ Cardiovasc Imaging. 2012 Jan;5(1):94-101
pubmed: 22135400
Nat Rev Cancer. 2001 Oct;1(1):46-54
pubmed: 11900251
J Natl Cancer Inst. 2015 Dec 06;108(5):
pubmed: 26640245
J Clin Med. 2020 Jan 09;9(1):
pubmed: 31936611
Cancer Immunol Immunother. 2012 Sep;61(9):1451-61
pubmed: 22310931
Radiol Oncol. 2018 Oct 18;52(4):365-369
pubmed: 30367809
Q J Nucl Med Mol Imaging. 2014 Sep;58(3):276-83
pubmed: 25265248
Nat Biotechnol. 2003 Apr;21(4):405-13
pubmed: 12652311
Nat Rev Clin Oncol. 2011 Sep 27;8(11):677-88
pubmed: 21946842
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2108-16
pubmed: 20577737
Nat Clin Pract Oncol. 2009 Jan;6(1):53-8
pubmed: 19015650